Marine-Lenhart syndrome refers to a variant of Graves disease where there are coexistent autonomous thyroid nodules. It is better described as Graves disease with coexistent multinodular goitre or nodular Graves disease 1.
The syndrome is rare with reported prevalence somewhere between 1-4.1% in patients with Graves disease 5,7.
Occurrence of Graves disease, with stimulatory autoantibodies to thyroid-stimulating hormone (TSH) receptor, with coexisting nodularity of the thyroid gland.
Depicts both nodules and thyroiditis. Features suggesting thyroiditis are:
- diffusely enlarged gland
- diffusely hypoechoic parenchyma
- markedly increased vascularity, so called "thyroid inferno"
Imaging appearances are those of a generally high degree of uptake (as in Graves disease) together with one or more nodules lacking significant uptake i.e. cold nodules.
In the course of therapy, along with normalisation of TSH levels, these initially cold nodules may alternate their degree of uptake, not infrequently changing to hot nodules 8,9.
Treatment and prognosis
Initial therapy usually consists of antithyroid drugs. Once thyroid hormone levels are under control, definite therapy options comprise:
- radionuclide therapy (once malignancy is ruled out) and
- surgery (which some authors prefer for multiple nodules).
History and etymology
It was first described in 1911 by the American surgeons David Marine and Carl H Lenhart in Cleveland, Ohio, on histopathological and iodine content studies of goitre. They encountered eight cases of synchronous goitre and adenoma 4,5.
A list of differential diagnoses for cold nodules comprise both benign and malignant entities, which have been quantified in one larger single-centre study 7:
- great majority comprising benign entities such as:
- autoimmune changes
- coexisting nodular goitre
- incidence of thyroid malignancy in ~10% of all nodules
Scintigraphically-cold nodules with sonographic features suspicious for malignancy are usually biopsied, especially before radioiodine therapy.
- 1. Intenzo CM, Depapp AE, Jabbour S et-al. Scintigraphic manifestations of thyrotoxicosis. Radiographics. 2003;23 (4): 857-69. Radiographics (full text) - doi:10.1148/rg.234025716 - Pubmed citation
- 2. Chandramouly B, Mann D, Cunningham RP et-al. Marine-Lenhart syndrome. Graves' disease with poorly functioning nodules. Clin Nucl Med. 1992;17 (11): 905-6. Pubmed citation
- 3. Biersack HJ, Biermann K. The Marine-Lenhart syndrome revisited. Wien. Klin. Wochenschr. 2011;123 (15-16): 459-62. Wien. Klin. Wochenschr. (abstract) - doi:10.1007/s00508-011-0029-5 - Pubmed citation
- 4. Marine D, Lenhart CH. Pathological anatomy of exophthalmic goiter. Arch Intern Med. 1911;8:265–316. http://archinte.jamanetwork.com/article.aspx?articleid=653460
- 5. Charkes ND. Graves' disease with functioning nodules (Marine-Lenhart syndrome). J. Nucl. Med. 1973;13 (12): 885-92. Pubmed citation
- 6. EFSUMB Course Book on Ultrasound. EFSUMB. ISBN:0957158106. Read it at Google Books - Find it at Amazon pp.537-41
- 7. Carnell NE, Valente WA. Thyroid nodules in Graves' disease: classification, characterization, and response to treatment. Thyroid. 1998;8 (8): 647-52. Pubmed citation
- 8. Waldherr C, Otte A, Haldemann A et-al. Marine-Lenhart syndrome: a case observation upon 18 years. Nuklearmedizin. 2000;38 (8): 345-8. Pubmed citation
- 9. Nygaard B, Faber J, Veje A et-al. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Thyroid. 1999;9 (5): 477-81. Pubmed citation